Pennsylvania saw a meteoric rise in the number of adolescents receiving puberty blockers through an insurance billing code currently being investigated under the Trump administration on fraud suspicions.
More than 220 claims for puberty-blocking drugs were reimbursed for minors aged 10-13 with the International Classification of Diseases billing code, E30.1, for precocious puberty between Jan. 1, 2013, and Dec. 31, 2024, costing taxpayers more than $1.8 million, according to the data. The number of claims in the 10-13 age group went from zero in 2012 and ballooned to 47 by 2016. The Department of Justice has raised concerns that this billing code may have been fraudulently used by gender doctors to obtain insurance coverage for sex-rejecting interventions.
“A spike of this magnitude in the diagnosis of
Continue reading
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!